Patients with severe COVID-19 have high levels of IL-6 (Mosharmovahed et al., 2020) and in three cohort studies, tocilizumab use was associated with lower mortality and ICU admission rate (Capra et al., 2020; Klopfenstein et al., 2020; Moreno-García et al., 2020). The gene discussed is IL6; the disease is COVID-19.